700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
He earned MD degree at the Medical Academy, Poznan followed by Residency/Fellowship in Molecular Medicine in Rigshospitalet, Copenhagen. He earned PhD at the Polish Academy of Sciences, Warsaw followed by the postdoctoral fellowships in molecular biology at the Austrian Academy of Sciences, Salzburg, ETH, Zurich, Utrecht University, Utrecht, Cancer Center, Vienna, Cancer Center, Amsterdam, Biozentrum, Basel. He is currently Associate Professor of Genetics, Genomics, and Gene Therapy at the Western University, Pomona, CA and President of Phoenix Biomolecular Engineering Foundation, San Francisco, CA.
Marek Malecki MD PhD developed a cancer suicide gene therapy. It was initially developed for ovarian cancers as the means of targeted elimination of cancer cells, while retaining healthy cells intact. This is the best way to retain women’s fertility in cases of cancer. It is based upon the synthetic scFv and probes, which he invented and patented (USPTO and WIPO). A big role in this gene therapy is played by the nuclear routing network, which he discovered during his tenure at the NIH, National Biotechnology Resource. He also developed the unique protocols of cryo-immobilization of living cells which retain their high viability.
Cancer of ovaries, cancer of testes, cancer stem cells (CSC), circulating tumor cells (CTCs), genetic disorders, iatrogenic genetic mutations, gene therapy, targeted gene delivery, site specific recombination, fertility sparing therapy, biobanking, in vitro fertilization.
Novel Approach for Designing Supportive Care in Genetic Disorders of Gastrointestinal Tract: Three-Dimensional Polymer Model of Nutritional Therapies in Cystic Fibrosis, Ulcerative Colitis, and Crohn`s Disease
Paul Zarogoulidis, Ioannis Kioumis, Theodora Tsiouda, Nikolaos Pezirkianidis, Christos Ritzoulis, Haidong Huang, Wolfgang Hohenforst-Schmidt, Dionysios Spyratos, Konstantinos Porpodis, Georgia Pitsiou, Nikolaos Pezirkianidis, Sofia Lampaki, John Organtzis, Konstantinos Zarogoulidis, Bianca Malecki, Marek Malecki
Research Article: J Nanomedine Biotherapeutic Discov 2014, 4: 128
Safeguarding Stem Cell-Based Regenerative Therapy against Iatrogenic Cancerogenesis: Transgenic Expression of DNASE1, DNASE1L3, DNASE2,DFFB Controlled By POLA1 Promoter in Proliferating and Directed Differentiation Resisting Human Autologous Pluripotent Induced Stem Cells Leads to their Death
Marek Malecki, Christine LaVanne, Dominique Alhambra, Chaitanya Dodivenaka, Sarah Nagel and Raf Malecki
Research Article: J Stem Cell Res Ther 2013, S9-005
Marek Malecki, Jessica Dahlke, Melissa Haig, Lynn Wohlwend and Raf Malecki
Research Article: J Genet Syndr Gene Ther 2013, 4: 152
Paul Zarogoulidis, Kaid Darwiche, Antonios Sakkas, Lonny Yarmus, Haidong Huang, Qiang Li, Lutz Freitag, Konstantinos Zarogoulidis and Marek Malecki
Review Article: J Genet Syndr Gene Ther 2013, 4: 139
Improved Targeting and Enhanced Retention of the Human, Autologous, Fibroblast-Derived, Induced, Pluripotent Stem Cells to the Sarcomeres of the Infarcted Myocardium with the Aid of the Bioengineered, Heterospecific, Tetravalent Antibodies
Research Article: J Stem Cell Res Ther 2013, 3:138